MiMedx Group Statistics
Total Valuation
MiMedx Group has a market cap or net worth of $984.41 million. The enterprise value is $904.83 million.
| Market Cap | 984.41M |
| Enterprise Value | 904.83M |
Important Dates
The next confirmed earnings date is Wednesday, April 30, 2025, after market close.
| Earnings Date | Apr 30, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
MiMedx Group has 147.37 million shares outstanding. The number of shares has increased by 2.12% in one year.
| Current Share Class | 147.37M |
| Shares Outstanding | 147.37M |
| Shares Change (YoY) | +2.12% |
| Shares Change (QoQ) | +0.59% |
| Owned by Insiders (%) | 1.63% |
| Owned by Institutions (%) | 44.62% |
| Float | 109.15M |
Valuation Ratios
The trailing PE ratio is 23.86 and the forward PE ratio is 24.97.
| PE Ratio | 23.86 |
| Forward PE | 24.97 |
| PS Ratio | 2.81 |
| Forward PS | 2.56 |
| PB Ratio | 5.08 |
| P/TBV Ratio | 6.08 |
| P/FCF Ratio | 15.26 |
| P/OCF Ratio | 14.87 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 13.85, with an EV/FCF ratio of 14.03.
| EV / Earnings | 21.33 |
| EV / Sales | 2.59 |
| EV / EBITDA | 13.85 |
| EV / EBIT | 15.26 |
| EV / FCF | 14.03 |
Financial Position
The company has a current ratio of 4.21, with a Debt / Equity ratio of 0.13.
| Current Ratio | 4.21 |
| Quick Ratio | 3.51 |
| Debt / Equity | 0.13 |
| Debt / EBITDA | 0.37 |
| Debt / FCF | 0.39 |
| Interest Coverage | 15.06 |
Financial Efficiency
Return on equity (ROE) is 25.01% and return on invested capital (ROIC) is 17.99%.
| Return on Equity (ROE) | 25.01% |
| Return on Assets (ROA) | 14.74% |
| Return on Invested Capital (ROIC) | 17.99% |
| Return on Capital Employed (ROCE) | 27.17% |
| Revenue Per Employee | $416,821 |
| Profits Per Employee | $50,680 |
| Employee Count | 837 |
| Asset Turnover | 1.39 |
| Inventory Turnover | 2.68 |
Taxes
In the past 12 months, MiMedx Group has paid $15.30 million in taxes.
| Income Tax | 15.30M |
| Effective Tax Rate | 26.70% |
Stock Price Statistics
The stock price has increased by +7.38% in the last 52 weeks. The beta is 1.74, so MiMedx Group's price volatility has been higher than the market average.
| Beta (5Y) | 1.74 |
| 52-Week Price Change | +7.38% |
| 50-Day Moving Average | 7.77 |
| 200-Day Moving Average | 7.54 |
| Relative Strength Index (RSI) | 32.25 |
| Average Volume (20 Days) | 587,473 |
Short Selling Information
The latest short interest is 4.71 million, so 3.20% of the outstanding shares have been sold short.
| Short Interest | 4.71M |
| Short Previous Month | 4.15M |
| Short % of Shares Out | 3.20% |
| Short % of Float | 4.31% |
| Short Ratio (days to cover) | 7.99 |
Income Statement
In the last 12 months, MiMedx Group had revenue of $348.88 million and earned $42.42 million in profits. Earnings per share was $0.28.
| Revenue | 348.88M |
| Gross Profit | 288.81M |
| Operating Income | 59.31M |
| Pretax Income | 63.47M |
| Net Income | 42.42M |
| EBITDA | 65.35M |
| EBIT | 59.31M |
| Earnings Per Share (EPS) | $0.28 |
Balance Sheet
The company has $104.42 million in cash and $24.84 million in debt, giving a net cash position of $79.57 million or $0.54 per share.
| Cash & Cash Equivalents | 104.42M |
| Total Debt | 24.84M |
| Net Cash | 79.57M |
| Net Cash Per Share | $0.54 |
| Equity (Book Value) | 193.11M |
| Book Value Per Share | 1.31 |
| Working Capital | 146.29M |
Cash Flow
In the last 12 months, operating cash flow was $66.20 million and capital expenditures -$1.68 million, giving a free cash flow of $64.51 million.
| Operating Cash Flow | 66.20M |
| Capital Expenditures | -1.68M |
| Free Cash Flow | 64.51M |
| FCF Per Share | $0.44 |
Margins
Gross margin is 82.78%, with operating and profit margins of 17.00% and 12.16%.
| Gross Margin | 82.78% |
| Operating Margin | 17.00% |
| Pretax Margin | 16.42% |
| Profit Margin | 12.16% |
| EBITDA Margin | 18.73% |
| EBIT Margin | 17.00% |
| FCF Margin | 18.49% |
Dividends & Yields
MiMedx Group does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.12% |
| Shareholder Yield | n/a |
| Earnings Yield | 4.31% |
| FCF Yield | 6.55% |
Analyst Forecast
The average price target for MiMedx Group is $12.00, which is 79.37% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $12.00 |
| Price Target Difference | 79.37% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
MiMedx Group has an Altman Z-Score of 11.1 and a Piotroski F-Score of 6.
| Altman Z-Score | 11.1 |
| Piotroski F-Score | 6 |